Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice

Pancreas

Volumn 42, Issue 1, 2013, Pages 123-129

  Li, Kun ^a   Feng, Jia Yan ^a   Li, Yong Yu ^a   Yuece, Birol ^b   Lin, Xu Hong ^a   Yu, Liang Ying ^a   Li, Yan Na ^a   Feng, Ya Jing ^a   Storr, Martin ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

acute pancreatitis; cannabidiol; GPR55; O 1602

Indexed keywords

CANNABIDIOL; CANNABINOID DERIVATIVE; CERULETIDE; CYTOKINE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; MYELOPEROXIDASE; O 1602; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; ENZYME ACTIVITY; LUNG; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; AMYLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CAERULEIN; CANNABIDIOL; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; LIPASE; LUNG; MICE; MICE, INBRED C57BL; PANCREAS; PANCREATITIS; PEROXIDASE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CANNABINOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872086511     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318259f6f0     Document Type: Article

References (41)

1. Hochman D, Louie B, Bailey R. Determination of patient quality of life following severe acute pancreatitis. Can J Surg. 2006;49:101-106.
2. Hayden P,Wyncoll D. Severe acute pancreatitis. Curr Anaesth Crit Care. 2008;19:1-7.
3. Bhatia M, Brady M, Shokuhi S, et al. Inflammatory mediators in acute pancreatitis. J Pathol. 2000;190:117-125.
4. Bhatia M. Therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets Inflamm Allergy. 2002;1:343-351.
5. de-Madaria E, Martinez J, Sempere L, et al. Cytokine genotypes in acute pancreatitis: association with etiology, severity, and cytokine levels in blood. Pancreas. 2008;37:295-301.
6. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389-462.
7. Faith RK, Nephi S. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther. 2009;122:83-96.
8. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol. 2004;141: 775-785.
9. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400-411.
10. Schicho R, Bashashati M, Bawa M, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitments. Inflamm Bowel Dis. 2011;17:1651-1664.
11. Wargo KA, Geveden BN, McConnell V. Cannabinoid-induced pancreatitis: a case series. JOP. 2007;8:579-583.
12. Belze O Jr, Legras A, Ehrmann S, et al. Cannabis-induced acute pancreatitis. J Emerg Med. 2011;131.e3-e4.
13. Michalski CW, Laukert T, Sauliunaite D, et al. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology. 2007;132:1968-1978.
14. Storr M, Kramer J, Michler T, et al. Acute experimental pancreatitis is ameliorated by activation of cannabinoid-1 (CB1) receptor. Gastroenterology. 2008;134:A430.
15. Zyromski NJ, Mathur A, Pitt HA, et al. Cannabinoid receptor-1 blockade attenuates acute pancreatitis in obesity by an adiponectin mediated mechanism. J Gastrointest Surg. 2009;13:831-838.
16. Dembinski A, Warzecha Z, Ceranowicz P, et al. Cannabinoids in acute gastric damage and pancreatitis. J Physiol Pharmacol. 2006;57:137-154.
17. Petrella C, Agostini S, Alema GS, et al. Cannabinoid agonist WIN55,212 in vitro inhibits interleukin-6 (IL-6) and monocyte chemo-attractant protein-1 (MCP-1) release by rat pancreatic acini and in vivo induces dual effects on the course of acute pancreatitis. Neurogastroenterol Motil. 2010;22:1248-1256.
18. Sawzdargo M, Nguyen T, Lee DK, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999;64:193-198.
19. Moriconi A, Cerbara I, Maccarrone M, et al. Gpr55: current knowledge and future perspectives of a purported ''type 3'' cannabinoid receptor. Curr Med Chem. 2010;17:1411-1429.
20. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid Receptor. Br J Pharmacol. 2007;152: 1092-1101.
21. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol. 2007;152:984-986.
22. Whytea LS, Rybergb E, Simsc NA, et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A. 2009;105:16511-16516.
23. Baker D, Pryce G, Davies WL, et al. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci. 2006;27:1-4.
24. Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol. 2007;152:825-831.
25. Mchugh D, Tanner C, Mechoulam R, et al. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol. 2008;73:441-450.
26. Li YY, Ochs S, Gao ZR, et al. Regulation of HSP60 and the role of MK2 in a new model of severe experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2009;297:G981-G989.
27. Cock HE, Forman MA, Farver TB, et al. Prevalence and histopathologic characteristics of pancreatitis in cats. Vet Pathol. 2007;44:39-49.
28. Magana GJ, Lopez CG, Barca A MC. Caerulin-induced pancreatitis in rats: histological and genetic expression changes from acute phase to recuperation. World J Gastroenterol. 2006;12:3999-4003.
29. Breljak D, Ambriovic R, Kapitnovic S, et al. Comparison of three RT-PCR based methods for relative quantification of mRNA. Food Technol Biotechnol. 2005;43:379-388.
30. Li XL, Li K, Li YY, et al. Alteration of Cpn60 expression in pancreatic tissue of rats with acute pancreatitis. Cell Stress Chaperones. 2009;14:199-206.
31. Lin XH, Yuece B, Li YY, et al. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol Motil. 2011;23:862-870.
32. Pandol SJ, Saluja AK, Imrie CW, et al. Acute pancreatitis: bench to the bedside. Gastroenterology. 2007;132:1127-1151.
33. Shen HN, Lu CL. Incidence, resource use, and outcome of acute pancreatitis with/without intensive care: a nationwide population-based study in Taiwan. Pancreas. 2011;40:10-15.
34. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci. 2009;30:156-163.
35. Gukovskaya AS, Gukovsky I, Zaninovic V, et al. Pancreatic acinar cells produce, release, and respond to rumor necrosis factor->. Role in regulating cell death and pancreatitis. J Clin Invest. 1997;100: 1853-1862.
36. Shimada M, Andoh A, Hata K, et al. Il-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol. 2002;168:861-868.
37. Granger J, Remick D. Acute pancreatitis: models, markers, and mediators. Shock. 2005;24:45-51.
38. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol recent advances. Chem Biodivers. 2007;4:1678-1692.
39. Ryan D, Drysdale AJ, Pertwee RG, et al. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci. 2007;25:2093-2102.
40. Filippis D, Iuvone T, damico A, et al. Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil. 2008;20:919-927.
41. O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology. 2010;215:611-616.